PI
KALV

PEAK6 Investments’s KalVista Pharmaceuticals KALV Stock Holding History

PEAK6 Investments’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$174K Hold
15,000
– – ﹤0.01% 2824
2024
Q2 		$177K Hold
15,000
– – ﹤0.01% 2813
2024
Q1 		$178K Buy
+15,000
New +$200K ﹤0.01% 3122

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PEAK6 Investments's KALV Position: Q3 2024 in Review

PEAK6 Investments held its KalVista Pharmaceuticals (KALV) position steady in Q3 2024 at 15,000 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #2824.

PEAK6 Investments first reported a position in KALV in Q1 2024 and has held it in 3 quarters since. The position peaked at $178K in Q1 2024. 122 funds tracked by Wall St. Rank hold KALV as of Q3 2024.

  • PEAK6 Investments held 15,000 shares of KalVista Pharmaceuticals worth $174K as of Q3 2024.
  • PEAK6 Investments left its KalVista Pharmaceuticals share count unchanged in Q3 2024.
  • KalVista Pharmaceuticals made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2824 holding.
  • PEAK6 Investments first reported a position in KalVista Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • PEAK6 Investments's KalVista Pharmaceuticals position peaked at $178K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.